Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-06-14
2011-06-14
Nolan, Jason M (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C546S157000, C546S158000
Reexamination Certificate
active
07960548
ABSTRACT:
Compounds and methods for treating, inhibiting, or delaying the onset of cancer in a subject by administering a therapeutically effective amount of a keratinocyte growth factor receptor tyrosine kinase (KGFR TK) inhibitor to the subject in need of such treatment. Also provided are compounds and methods for the treating, inhibiting, or delaying the onset of metastasis in a subject with cancer by administering a therapeutically effective amount of a KGFR TK inhibitor to the subject in need of such treatment.
REFERENCES:
patent: 3330823 (1967-07-01), Bernstein et al.
patent: 5023261 (1991-06-01), Kamijo et al.
patent: 5348962 (1994-09-01), Kulagowski et al.
patent: 6716880 (2004-04-01), Li et al.
patent: 6855726 (2005-02-01), Dudley et al.
patent: WO 9950263 (1999-10-01), None
patent: WO 02051835 (2002-07-01), None
patent: WO 03020698 (2003-03-01), None
patent: 2006/119148 (2006-11-01), None
Kanaoka et al. Tetrahedron Letters 1980, 21(40), 3893-6.
Kappe et al. Chemische Berichte 1978, 111(12), 3857-66, (CAS Abstract and Structures attached).
Hubner et al. Berichte der Deutschen Chemischen Gesellschaft 1908, 41, 482-7, (CAS Abstract and structure attached).
Collington et al. Journal of the Chemical Society C: Organic 1968, 8, 1017-20. The CAS abstract and chemical structure of 3,4-dihydro-3-(2-methoxyphenyl)-1(1H)-quinolinone are provided.
Wislicenus et al. Annalen der Chemie, Justus Liebigs 1920, 421, 119-58; the CAS abstract and structure are attached.
Hey et al. Journal of the Chemical Society 1949, 3164-71; the CAS abstract and structure are attached.
Walser et al. Journal of Heterocyclic Chemistry 1975, 12(2), 351-8; the CAS abstract and structure are attached.
Xiao et al. Bioorganic & Medicinal Chemistry Letters 2001, 11, 2875-78.
El Ali et al. J. Am. Chem. Soc. 1996, 118, 4264-4270.
Uray et al. Helvetica Chemica Acta 1999, 82(9), 1408-1417.
Li et al. Bioorg. Med. Chem. Lett. 2001, 11, 1687-90.
Zang, Xiao-Ping, et al., “KGF-induced motility of breast cancer cells is dependent on Grb2 and Erk1,2,” Clinical & Experimental Metastasis 21, pp. 437-443, 2004, Kluwer Academic Publishers, Netherlands.
Zang, Xiao-Ping, et al., “Keratinocyte growth factor-induced motiblity of breast cancer cells,” Clinical & Experimental Metastasis 18, pp. 573-580, 2001, Kluwer Academic Publishers, Netherlands.
International Search Report mailed Sep. 25, 2007 for WO 2006/119148 A2.
Written Opinion mailed Sep. 25, 2007 for WO 2006/119148 A2.
International Preliminary Report on Patentability issued Oct. 30, 2007 for WO 2006/119148 A2.
Brueggemeier Robert W.
Hackett John C.
Li Pui-Kai
Pento J. Thomas
Calfee Halter & Griswold LLP
Nolan Jason M
The Board of Regents of the University of Oklahoma
The Ohio State University Research Foundation
LandOfFree
Keratinocyte growth factor receptor—tyrosine specific... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Keratinocyte growth factor receptor—tyrosine specific..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Keratinocyte growth factor receptor—tyrosine specific... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2730856